Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
Most relevant news about CELGENE CORPORATION
06:02aCELGENE : Inhibiting EIF2AK1 could help treat sickle cell disease
AQ
07/12CELGENE CORPORATION : - Anti-PD-L1 Immunotherapy Plus ABRAXANE Significantly Red..
AQ
07/11CELGENE : and Acceleron Announce Luspatercept Achieved Primary and All Key Secon..
AQ
07/11ACCELERON PHARMA : Latest luspatercept readout a second win for Acceleron, Celge..
AQ
07/10CELGENE : Health Care Shares Move Higher as Focus Shifts to Earnings -- Health C..
DJ
07/10CELGENE : Anti-PD-L1 Immunotherapy Plus ABRAXANE® Significantly Reduced the Risk..
BU
07/10CELGENE : Golumbeski resurfaces, at Grail
AQ
07/09CELGENE : and Acceleron Announce Luspatercept Achieved Primary and All Key Secon..
PU
07/09CELGENE : Acceleron Say Trial on Blood-Disorder Drug Yields Positive Results -- ..
DJ
07/09CELGENE : and Acceleron Announce Positive Results From Blood-Disorder Drug Trial..
DJ
07/06CELGENE CORPORATION : to Announce Second Quarter 2018 Results on July 26, 2018
AQ
07/05CELGENE : Accord Healthcare Resolve Revlimid Patent Dispute -- Update
DJ
07/05CELGENE : Accord Healthcare Resolve Revlimid Patent Dispute
DJ
07/03CELGENE : and Acceleron Announce Luspatercept Achieved Primary and Key Secondary..
AQ
07/02CELGENE CORPORATION : to Announce Second Quarter 2018 Results on July 26, 2018
BU
More most relevant news
All news about CELGENE CORPORATION
06:02aCELGENE : Inhibiting EIF2AK1 could help treat sickle cell disease
AQ
07/12CELGENE : and Acceleron Announce Luspatercept Achieved Primary and Key Secondary..
AQ
07/12CELGENE CORPORATION : - Anti-PD-L1 Immunotherapy Plus ABRAXANE Significantly Red..
AQ
07/11CELGENE : and Acceleron Announce Luspatercept Achieved Primary and All Key Secon..
AQ
07/11TODAY'S RESEARCH REPORTS ON TRENDING : Galapagos and Celgene
AC
07/11CELGENE : and Acceleron Announce Luspatercept Achieved Primary and All Key Secon..
AQ
07/11ACCELERON PHARMA : Latest luspatercept readout a second win for Acceleron, Celge..
AQ
07/10CELGENE : Health Care Shares Move Higher as Focus Shifts to Earnings -- Health C..
DJ
07/10CELGENE : Anti-PD-L1 Immunotherapy Plus ABRAXANE® Significantly Reduced the Risk..
BU
07/10CELGENE : Golumbeski resurfaces, at Grail
AQ
More news
Sector news : Pharmaceuticals - NEC
03:06aBattle lines drawn as EU court weighs fate of gene-edited crops
RE
02:48aMERCK AND : to Cut Drug Prices Amid Pressure -- WSJ
DJ
02:16aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
07/19AMGEN : and Cedars-Sinai in Collaboration for 'Health-Care Quality'
DJ
07/19MERCK AND : to Limit Drug-Price Increases, Cut Some Prices
DJ
07/19MERCK AND : Announces Plan to Lower Prices of Some Drugs
DJ
More sector news : Pharmaceuticals - NEC
Official Publications
05/04SEC Filing 8K 
05/041st quarter results 
05/04Slide show Q1 results 
03/31SEC Filing 10Q-1 
01/26Slide show results 
01/26SEC Filing 8K 
More official Publications
News from SeekingAlpha
07/19Big Pharma in the red on ramped up pressure on drug prices 
07/18FDA committed to easing approval path for biosimilars 
07/18You Can't Go Wrong Buying Netflix On Dips - Cramer's Mad Money (7/17/18) 
07/16CVS responds to Trump Administration's request for info on now to lower drug .. 
07/16The Smart Way To Find Undervalued Stocks 
07/16BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Celgene's Protocol Change, Roche's BLA Fo.. 
Latest Tweets
11:02aCelgene $CELG Downgraded by Zacks Investment Research to “Sell”  
07/19Traders Sell Shares of Celgene $CELG on Strength $CELG  
07/19Andrew Smith, Director of FTC's Bureau of Consumer Protection: What we are do..
1
07/19$JUNO $CELG JCAR015 ROCKET results posted on https://t.co/sPCDmMSXWC (termina..
5
07/19"The UK government must stop arming and supporting tyrants and dictatorships ..
19
More tweets
Qtime:431
Financials ($)
Sales 2018 14 928 M
EBIT 2018 8 448 M
Net income 2018 4 834 M
Debt 2018 11 631 M
Yield 2018 -
P/E ratio 2018 13,39
P/E ratio 2019 10,53
EV / Sales 2018 4,94x
EV / Sales 2019 4,04x
Capitalization 62 176 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 113 $
Spread / Average Target 32%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman, President, CEO & COO
Peter N. Kellogg Executive VP, Chief Financial & Accounting Officer
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Jay T. Backstrom Chief Medical Officer
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-18.23%62 176
JOHNSON & JOHNSON-8.53%346 292
PFIZER3.98%220 236
ROCHE HOLDING LTD.-5.90%200 995
NOVARTIS-1.75%200 139
MERCK AND COMPANY11.09%168 225